Nitrazepam

證據等級: L5

預測適應症: 3 個

Nitrazepam: From Sedative-Hypnotic to Sleep Disorder (Initiating and Maintaining Sleep)

One-Sentence Summary

Nitrazepam is a benzodiazepine compound known internationally as a sedative-hypnotic; it carries no current marketing authorization in the Netherlands. The TxGNN model predicts it may be effective for sleep disorder, initiating and maintaining sleep, with a prediction score of 99.89%. This direction is supported by 0 registered clinical trials and 20 publications, and notably aligns with the drug’s established pharmacological use in countries where it is authorized — making this a regulatory access question as much as a scientific one.

Quick Overview

Item	Content
Original Indication	No NL (CBG-MEB) authorization on record; internationally known as a sedative-hypnotic
Predicted New Indication	Sleep disorder, initiating and maintaining sleep
TxGNN Prediction Score	99.89%
Evidence Level	L3 (clinical comparison studies and reviews; no registered Phase 2/3 trials)
NL Market Status	Not registered
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Nitrazepam belongs to the benzodiazepine class. Benzodiazepines act as positive allosteric modulators of the GABA-A receptor, enhancing the inhibitory effect of gamma-aminobutyric acid in the central nervous system. This produces sedative, hypnotic, anxiolytic, and anticonvulsant effects — mechanisms that are directly relevant to the initiation and maintenance of sleep.

The predicted indication is not a novel repurposing in the classical sense. Nitrazepam’s hypnotic use has been established for decades in countries including the United Kingdom, Japan, and Canada, where it is marketed under brand names such as Mogadon. The TxGNN model’s high prediction score (99.89%) reflects this strong mechanistic and clinical alignment. Multiple comparative studies in the literature confirm nitrazepam’s efficacy as a hypnotic, showing performance comparable to triazolam, flunitrazepam, brotizolam, and zolpidem in head-to-head clinical studies.

The key question for the Netherlands context is therefore not whether nitrazepam works for insomnia, but whether its benefit-risk profile — particularly risks of dependence (documented as early as 1975), next-day residual sedation, and cognitive impairment in elderly populations — justifies pursuing market access in an environment where CBG-MEB/EMA has authorized several alternative agents and where Dutch clinical guidelines (NHG-standaard) increasingly favour non-pharmacological first-line approaches such as cognitive behavioural therapy for insomnia (CBT-I).

Clinical Trial Evidence

Currently no related clinical trials are registered for Nitrazepam in the indication of sleep disorder (initiating and maintaining sleep).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
4892037	1969	Clinical trial (double-blind)	British Medical Journal	27 overdose patients and a double-blind ward trial: nitrazepam was as effective as butobarbitone as a hypnotic with no untoward effects even at high doses. Concluded safe and effective.
6135296	1983	RCT (double-blind cross-over)	Acta Psychiatrica Scandinavica	26 geriatric inpatients: triazolam 0.25 mg vs nitrazepam 5 mg. Sleep quantity, quality, and psychomotor performance were similar for both drugs.
7037262	1981	Review	Clinical Pharmacokinetics	Comprehensive pharmacokinetics review of nitrazepam, covering half-life, distribution, and dosing implications — foundational for clinical use planning.
3281819	1988	Review	Drugs	Brotizolam pharmacology review with direct clinical comparison to nitrazepam 2.5–5 mg: efficacy for insomnia was equivalent across controlled trials.
10804040	2000	Review	Drugs	Zolpidem update: hypnotic efficacy comparable to nitrazepam, flurazepam, flunitrazepam, and temazepam in elderly insomniacs; positions nitrazepam within the benzodiazepine comparator landscape.
15089115	2004	Review	CNS Drugs	Reviews epidemiological evidence linking hypnotics including nitrazepam to next-day psychomotor impairment, increased accident risk, and clinical management implications.
19450355	2007	Review	BMJ Clinical Evidence	Up to 40% of adults experience insomnia; prevalence increases with age. Reviews risk factors, diagnosis, and evidence-based treatment options relevant to positioning any hypnotic.
14960254	2004	HTA / RCT	Health Technology Assessment	CBT-I evaluated in long-term hypnotic users (including nitrazepam users) in UK general practice; demonstrates that psychological treatment can reduce dependence on drugs like nitrazepam.
1125532	1975	Case report	British Journal of Psychiatry	Early documentation of nitrazepam (Mogadon) dependence — a key safety signal directly relevant to long-term insomnia management risk assessment.
39231170	2024	Observational	PLoS One	Benzodiazepine prescribing pattern analysis in primary care: long-term use associated with dependence, tolerance, and cognitive decline, especially in older adults. Reinforces the need for careful prescribing and deprescribing strategies.

Netherlands Market Information

Nitrazepam currently holds no CBG-MEB marketing authorization in the Netherlands and is not listed in the NL medicines registry. No approved indications, dosage forms, or RVG numbers are on record.

Clinicians wishing to use nitrazepam in the Netherlands would need to pursue one of the following pathways:

Magistrale bereiding (extemporaneous compounding) — subject to Dutch pharmacy regulations under the Geneesmiddelenwet
Named-patient import — requires CBG-MEB notification and justification under Article 40(3) of the Dutch Medicines Act
Full marketing authorization application — via the EMA centralized procedure or CBG-MEB national procedure

Currently authorized alternatives in the Netherlands for insomnia include temazepam, lormetazepam, and zolpidem, all of which would serve as the relevant clinical comparators in any regulatory submission.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for full safety information, as no drug-specific warnings or contraindication data were available in this evidence pack.

Based on the benzodiazepine drug class and literature evidence retrieved, the following class-level considerations are clinically relevant:

Dependence and withdrawal: Documented nitrazepam dependence exists (PMID 1125532); consistent with general benzodiazepine class risk
Residual sedation: Next-day psychomotor impairment and increased accident risk reported (PMID 15089115); particularly relevant for elderly and driving populations
Elderly populations: Increased sensitivity to sedative effects and cognitive impairment; dosing adjustment typically required
Long-term use: Associated with tolerance, dependence, and cognitive decline in primary care settings (PMID 39231170)

Conclusion and Next Steps

Decision: Hold

Rationale: While the literature clearly supports nitrazepam’s efficacy as a hypnotic for insomnia, the drug has no NL marketing authorization, no registered clinical trials for this indication, and known risks of dependence and residual sedation that require active risk management. Additionally, the predicted indication aligns with the drug’s established pharmacological use — not a novel repurposing — making the regulatory and clinical positioning strategy the primary barrier rather than lack of efficacy evidence.

To proceed, the following is needed:

Confirm full mechanism of action documentation via DrugBank API or EMA assessment reports (currently a data gap)
Obtain the SmPC from a country where nitrazepam is authorized (e.g., UK, Japan) to extract formal warnings and contraindications
Conduct a regulatory feasibility analysis: assess the named-patient import or full marketing authorization pathway with CBG-MEB
Review Dutch clinical guidelines (NHG-standaard Slaapproblemen en Slaapmiddelen) to determine whether nitrazepam could be positioned relative to authorized alternatives
Develop a risk management framework covering dependence monitoring, appropriate patient selection (excluding elderly as first-line), maximum treatment duration, and deprescribing protocols
Conduct a formal benefit-risk comparison against currently authorized NL hypnotics (temazepam, lormetazepam, zolpidem) to justify the regulatory submission rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.